What is the share price of Poly Medicure Ltd (POLYMED) today?
The share price of POLYMED as on 23rd June 2025 is ₹2122. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Poly Medicure Ltd (POLYMED) share?
The past returns of Poly Medicure Ltd (POLYMED) share are- Past 1 week: -7.01%
- Past 1 month: -16.28%
- Past 3 months: -8.11%
- Past 6 months: -20.62%
- Past 1 year: 2.96%
- Past 3 years: 208.56%
- Past 5 years: 593.62%
What are the peers or stocks similar to Poly Medicure Ltd (POLYMED)?
The peers or stocks similar to Poly Medicure Ltd (POLYMED) include:What is the dividend yield % of Poly Medicure Ltd (POLYMED) share?
The current dividend yield of Poly Medicure Ltd (POLYMED) is 0.16.What is the market cap of Poly Medicure Ltd (POLYMED) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Poly Medicure Ltd (POLYMED) is ₹21639.12 Cr as of 23rd June 2025.What is the 52 week high and low of Poly Medicure Ltd (POLYMED) share?
The 52-week high of Poly Medicure Ltd (POLYMED) is ₹3357.80 and the 52-week low is ₹1810.15.What is the PE and PB ratio of Poly Medicure Ltd (POLYMED) stock?
The P/E (price-to-earnings) ratio of Poly Medicure Ltd (POLYMED) is 63.92. The P/B (price-to-book) ratio is 14.72.Which sector does Poly Medicure Ltd (POLYMED) belong to?
Poly Medicure Ltd (POLYMED) belongs to the Health Care sector & Health Care Equipment & Supplies sub-sector.How to buy Poly Medicure Ltd (POLYMED) shares?
You can directly buy Poly Medicure Ltd (POLYMED) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Poly Medicure Ltd
POLYMED Share Price
How to use scorecard? Learn more
POLYMED Performance & Key Metrics
POLYMED Performance & Key Metrics
No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
---|---|---|
63.92 | 14.72 | 0.16% |
Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
---|---|---|
35.65 | 6.54 | 0.85% |
from 5 analysts
Price Upside
Earnings Growth
Rev. Growth
POLYMED Company Profile
Poly Medicure Limited is engaged in the manufacturing and sale of medical devices.
POLYMED Sentiment Analysis
POLYMED Sentiment Analysis
POLYMED Stock Summary · May 2025
Poly Medicure Limited demonstrated robust financial performance in FY '25, achieving a 21.5% revenue growth driven by a remarkable 60% increase in its Renal business. While the company is strategically shifting focus towards the domestic market, anticipating a 30%-32% growth, it remains cautious about export challenges, particularly in Europe. A significant capital expenditure plan of Rs. 500 crores aims to enhance manufacturing capabilities, supported by a commitment to innovation reflected in 334 global patents. Despite a reduced dividend payout ratio to conserve cash for potential mergers and acquisitions, management emphasizes operational efficiency and market competitiveness, positioning itself for sustainable growth amidst evolving market dynamics.
POLYMED Stock Growth Drivers
POLYMED Stock Growth Drivers
8Strong Financial Performance
Poly Medicure Limited has reported significant financial achievements, including a consolidated revenue increase from Rs.
Successful Product Launches and Innovations
The company has accelerated its product development, launching approximately 30 new products in FY '25,
POLYMED Stock Challenges
POLYMED Stock Challenges
4Decreasing Government Revenue
The company has experienced a decline in government revenue, which now constitutes approximately 10% to
Poor Margins in Renal Business
The company is currently facing poor margins in its Renal business due to its early-stage
POLYMED Forecast
POLYMED Forecasts
Price
Revenue
Earnings
POLYMED Share Price Forecast
POLYMED Share Price Forecast
All values in ₹
All values in ₹
POLYMED Company Revenue Forecast
POLYMED Company Revenue Forecast
All values in ₹ Thousand cr.
All values in ₹ Thousand cr.
POLYMED Stock EPS (Earnings Per Share) Forecast
POLYMED Stock EPS (Earnings Per Share) Forecast
All values in ₹
All values in ₹
POLYMED
POLYMED
Income
Balance Sheet
Cash Flow
POLYMED Income Statement
POLYMED Income Statement
Financial Year | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenue | 468.95 | 536.04 | 630.50 | 707.84 | 808.20 | 963.41 | 1,153.34 | 1,437.07 | 1,764.14 | 1,764.13 | ||||||||||
Raw Materials | 119.62 | 176.07 | 165.66 | 178.89 | 214.22 | 296.55 | 345.37 | 382.51 | 1,216.99 | 1,216.59 | ||||||||||
Power & Fuel Cost | 16.78 | 19.04 | 24.74 | 25.62 | 25.27 | 29.84 | 38.59 | 44.29 | ||||||||||||
Employee Cost | 87.26 | 99.13 | 116.61 | 138.76 | 141.76 | 163.62 | 202.75 | 245.91 | ||||||||||||
Selling & Administrative Expenses | 47.08 | 45.24 | 58.05 | 61.03 | 56.20 | 66.97 | 77.78 | 95.63 | ||||||||||||
Operating & Other expenses | 90.80 | 58.98 | 114.53 | 116.82 | 132.53 | 151.07 | 183.34 | 246.97 | ||||||||||||
EBITDA | 107.41 | 137.58 | 150.91 | 186.72 | 238.22 | 255.36 | 305.51 | 421.76 | 547.15 | 547.54 | ||||||||||
Depreciation/Amortization | 23.73 | 29.24 | 37.29 | 40.53 | 47.52 | 53.95 | 57.17 | 63.93 | 82.64 | 83.04 | ||||||||||
PBIT | 83.68 | 108.34 | 113.62 | 146.19 | 190.70 | 201.41 | 248.34 | 357.83 | 464.51 | 464.50 | ||||||||||
Interest & Other Items | 8.49 | 11.58 | 13.53 | 20.48 | 10.64 | 6.16 | 10.86 | 13.56 | 12.00 | 12.00 | ||||||||||
PBT | 75.19 | 96.76 | 100.09 | 125.71 | 180.06 | 195.25 | 237.48 | 344.27 | 452.51 | 452.50 | ||||||||||
Taxes & Other Items | 20.06 | 26.16 | 34.67 | 29.85 | 44.18 | 48.74 | 58.21 | 86.01 | 113.95 | 113.97 | ||||||||||
Net Income | 55.13 | 70.60 | 65.42 | 95.86 | 135.88 | 146.51 | 179.27 | 258.26 | 338.56 | 338.53 | ||||||||||
EPS | 6.25 | 8.00 | 7.41 | 10.86 | 14.76 | 15.28 | 18.69 | 26.91 | 34.13 | 35.27 | ||||||||||
DPS | 2.50 | 2.00 | 2.00 | 2.00 | 2.50 | 2.50 | 3.00 | 3.00 | 3.50 | 3.00 | ||||||||||
Payout ratio | 0.40 | 0.25 | 0.27 | 0.18 | 0.17 | 0.16 | 0.16 | 0.11 | 0.10 | 0.09 |
POLYMED Company Updates
POLYMED Stock Peers
POLYMED Past Performance & Peer Comparison
POLYMED Past Performance & Peer Comparison
Health CareHealth Care Equipment & Supplies
Valuation
Technical
Forecast
Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
---|---|---|---|
Poly Medicure Ltd | 63.92 | 14.72 | 0.16% |
Inventurus Knowledge Solutions Ltd | 58.58 | 24.59 | — |
Laxmi Dental Ltd | 70.37 | 50.18 | — |
Tarsons Products Ltd | 66.85 | 3.25 | — |
POLYMED Stock Price Comparison
Compare POLYMED with any stock or ETFPOLYMED Holdings
POLYMED Shareholdings
POLYMED Promoter Holdings Trend
POLYMED Promoter Holdings Trend
In last 6 months, promoter holding in the company has almost stayed constant
Pledged promoter holdings is insignificant
POLYMED Institutional Holdings Trend
POLYMED Institutional Holdings Trend
In last 3 months, retail holding in the company has almost stayed constant
In last 3 months, foreign institutional holding of the company has almost stayed constant
POLYMED Shareholding Pattern
POLYMED Shareholding Pattern
POLYMED Shareholding History
POLYMED Shareholding History
Mutual Funds Invested in POLYMED
Mutual Funds Invested in POLYMED
In last 3 months, mutual fund holding of the company has almost stayed constant
Top 5 Mutual Funds holding Poly Medicure Ltd
Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 3.3388% | Percentage of the fund’s portfolio invested in the stock 2.56% | Change in the portfolio weight of the stock over the last 3 months -0.16% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 9/112 (-1) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 1.4639% | Percentage of the fund’s portfolio invested in the stock 1.25% | Change in the portfolio weight of the stock over the last 3 months -0.04% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 43/64 (-3) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.5287% | Percentage of the fund’s portfolio invested in the stock 3.10% | Change in the portfolio weight of the stock over the last 3 months -0.22% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 14/32 (-4) |
Compare 3-month MF holding change on Screener
smallcases containing POLYMED stock
smallcases containing POLYMED stock
Looks like this stock is not in any smallcase yet.
POLYMED Events
POLYMED Events
POLYMED Dividend Trend
POLYMED has increased or maintained dividend levels over the last 5 years
Current dividend yield is 0.16%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹1.55 every year
Dividends
Corp. Actions
Announcements
Legal Orders
POLYMED Dividend Trend
POLYMED has increased or maintained dividend levels over the last 5 years
Current dividend yield is 0.16%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹1.55 every year
POLYMED Upcoming Dividends
POLYMED Upcoming Dividends
No upcoming dividends are available
POLYMED Past Dividends
POLYMED Past Dividends
Cash Dividend
Ex DateEx DateSep 19, 2024
Dividend/Share
₹3.00
Ex DateEx Date
Sep 19, 2024
Cash Dividend
Ex DateEx DateSep 21, 2023
Dividend/Share
₹3.00
Ex DateEx Date
Sep 21, 2023
Cash Dividend
Ex DateEx DateSep 16, 2022
Dividend/Share
₹2.50
Ex DateEx Date
Sep 16, 2022
Cash Dividend
Ex DateEx DateSep 16, 2021
Dividend/Share
₹2.50
Ex DateEx Date
Sep 16, 2021
Cash Dividend
Ex DateEx DateFeb 27, 2020
Dividend/Share
₹2.00
Ex DateEx Date
Feb 27, 2020
POLYMED Stock News & Opinions
POLYMED Stock News & Opinions
Poly Medicure announced that the Board of Directors of the Company at its meeting held on 6 May 2025, inter alia, have recommended the final dividend of Rs 3.5 per equity Share (i.e. 70%) , subject to the approval of the shareholders.Powered by Capital Market - Live
Net profit of Poly Medicure rose 34.33% to Rs 91.83 crore in the quarter ended March 2025 as against Rs 68.36 crore during the previous quarter ended March 2024. Sales rose 16.60% to Rs 440.83 crore in the quarter ended March 2025 as against Rs 378.07 crore during the previous quarter ended March 2024. For the full year,net profit rose 31.09% to Rs 338.56 crore in the year ended March 2025 as against Rs 258.26 crore during the previous year ended March 2024. Sales rose 21.37% to Rs 1669.83 crore in the year ended March 2025 as against Rs 1375.80 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales440.83378.07 17 1669.831375.80 21 OPM %27.1025.51 -27.1226.00 - PBDT143.88108.54 33 535.15407.71 31 PBT122.8592.46 33 452.52344.27 31 NP91.8368.36 34 338.56258.26 31 Powered by Capital Market - Live
Poly Medicure will hold a meeting of the Board of Directors of the Company on 6 May 2025.Powered by Capital Market - Live
Poly Medicure has incorporated a wholly owned Step down subsidiary named Polyhealth in England and Wales on 04 February 2025. Polyhealth will be engaged in maufacturing and distribution of Medical Devices with great experiences for its customers. The focus will be on the supply chain and cater the Medical Devices market and/or any other activities ancillary and incidental thereto in in England and wales and other parts of Europe also. Powered by Capital Market - Live
The revenue growth was driven by the firm's robust market presence and effective growth strategies. Profit before tax increased 28.93% year on year (YoY) to Rs 113.23 crore in the quarter ended 31 December 2023. EBITDA grew 27.9% YoY to Rs 116.3 crore during the quarter. EBITDA margin improved to 27.4% in Q3 FY25, compared to 26.8% posted in Q3 FY24. Total expenses in Q3 FY25 were at Rs 334.51 crore, up 24.33% YoY. Cost of materials consumed was Rs 141.95 crore (up 19.57% YoY) while employee benefits expense stood at Rs 77.89 crore (up 28.96% YoY) during the period under review. On nine-month basis, the company's consolidated net profit climbed 29.92% to Rs 246.72 crore on 23.18% rise in revenue to Rs 1,229 crore in Q3 FY25 over Q3 FY24. Export revenue for the nine months increased by 29% YoY, driven by continued strong performance in key international markets. The domestic quarterly and nine-month revenue growth of 24% and 17% YoY respectively on a YoY basis, demonstrating the company's continued investments in building R&D and sales capabilities. Himanshu Baid, managing director, Poly Medicure stated: 'We are extremely pleased with our continued growth in the business in the last quarter. Overall revenue grew by almost 25% with EBITDA and PAT growing by 28% and 31% respectively. We are on track to achieve our revenue growth guidance of 22-24% while improving our EBITDA margin by 100 ' 150 bps. I am very excited to share that we have received regulatory approval to launch our Drug Eluting Stent and commercialisation of that is expected soon. That will give a significant fillip to our Cardiology business. We continue to invest aggressively in building our manufacturing capacities and recently ground-breaking ceremony was held at our Palwal Plant, which will be the largest plant that we would be seƫng up at a single location. We have also signed a JV agreement to set up a 10MW Solar Power plant in Haryana where we will own 26% stake. This will go a long way in achieving our sustainability goals and reduce our carbon-footprint. We are very excited about the growth opportunity that India provides in the MedTech sector and our continued investments strongly reflects in that belief.' Poly Medicure exports plastic medical disposables/surgical devices. It manufactures and supplies approximately 100 types of disposable medical devices in the product verticals of infusion therapy, anesthesia, urology, gastroenterology, blood management and blood collection, surgery and wound drainage, dialysis and central venous access catheters. Powered by Capital Market - Live
NLC India Ltd, Prudent Corporate Advisory Services Ltd, Redtape Ltd and Nuvama Wealth Management Ltd are among the other gainers in the BSE's 'A' group today, 04 February 2025.Poly Medicure Ltd soared 10.29% to Rs 2518.55 at 11:48 IST. The stock was the biggest gainer in the BSE's 'A' group. On the BSE, 9522 shares were traded on the counter so far as against the average daily volumes of 6553 shares in the past one month. NLC India Ltd surged 10.25% to Rs 232.9. The stock was the second biggest gainer in 'A' group. On the BSE, 7.94 lakh shares were traded on the counter so far as against the average daily volumes of 75652 shares in the past one month. Prudent Corporate Advisory Services Ltd spiked 9.42% to Rs 2199.3. The stock was the third biggest gainer in 'A' group. On the BSE, 4479 shares were traded on the counter so far as against the average daily volumes of 3548 shares in the past one month. Redtape Ltd jumped 9.39% to Rs 198. The stock was the fourth biggest gainer in 'A' group. On the BSE, 52286 shares were traded on the counter so far as against the average daily volumes of 9962 shares in the past one month. Nuvama Wealth Management Ltd gained 8.70% to Rs 5551.05. The stock was the fifth biggest gainer in 'A' group. On the BSE, 7669 shares were traded on the counter so far as against the average daily volumes of 7409 shares in the past one month. Powered by Capital Market - Live
Net profit of Poly Medicure rose 31.08% to Rs 85.23 crore in the quarter ended December 2024 as against Rs 65.02 crore during the previous quarter ended December 2023. Sales rose 24.91% to Rs 424.21 crore in the quarter ended December 2024 as against Rs 339.60 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales424.21339.60 25 OPM %27.0026.57 - PBDT134.74104.04 30 PBT113.2387.82 29 NP85.2365.02 31 Powered by Capital Market - Live
Poly Medicure will hold a meeting of the Board of Directors of the Company on 3 February 2025.Powered by Capital Market - Live
Poly Medicure has entered into a joint venture agreement with AMPIN C&I Power for the purpose of setting up a Solar Power Project, which will be set up to supply power to the Company as a captive generating plant for Company's manufacturing facility, in Haryana, India. Pursuant to the said JV Agreement, the proposed JV Company will be 26% owned by Poly Medicure and 74% owned by AMPIN C&I Power. Powered by Capital Market - Live
Adani Green Energy Ltd, DCM Shriram Ltd, Fortis Healthcare Ltd and Emami Ltd are among the other losers in the BSE's 'A' group today, 26 November 2024.Poly Medicure Ltd tumbled 7.27% to Rs 2784.4 at 14:47 IST.The stock was the biggest loser in the BSE's 'A' group.On the BSE, 21486 shares were traded on the counter so far as against the average daily volumes of 14968 shares in the past one month.Adani Green Energy Ltd lost 6.47% to Rs 905. The stock was the second biggest loser in 'A' group.On the BSE, 3.82 lakh shares were traded on the counter so far as against the average daily volumes of 2.73 lakh shares in the past one month.DCM Shriram Ltd crashed 5.49% to Rs 1159.95. The stock was the third biggest loser in 'A' group.On the BSE, 19312 shares were traded on the counter so far as against the average daily volumes of 15940 shares in the past one month.Fortis Healthcare Ltd plummeted 4.92% to Rs 666.25. The stock was the fourth biggest loser in 'A' group.On the BSE, 49929 shares were traded on the counter so far as against the average daily volumes of 46145 shares in the past one month.Emami Ltd corrected 4.27% to Rs 663.45. The stock was the fifth biggest loser in 'A' group.On the BSE, 18549 shares were traded on the counter so far as against the average daily volumes of 17507 shares in the past one month.Powered by Capital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 17.91%, vs industry avg of 17.66%
Over the last 5 years, market share decreased from 52.57% to 26.31%
Over the last 5 years, net income has grown at a yearly rate of 31.6%, vs industry avg of 3.47%